Zobrazeno 1 - 10
of 1 048
pro vyhledávání: ''
Autor:
Yan Yuan, Zhifan Zeng, Rong-Zhen Li, Weiwei Xiao, Hui Chang, Qiaoxuan Wang, Yuanhong Gao, Wei-Hao Xie
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 117-127 (2022)
Cancer Medicine
Cancer Medicine
Background Anal squamous cell carcinoma (ASCC) is a rare malignant tumor with increasing incidence. The goal of our study was to analyze the treatment outcome and prognostic factors of ASCC in South China in the past half‐century. Methods This stud
Autor:
Tam N M Ngo, Jan Mazur, Eugene S. Chung, Huy Gia Vuong, Vien T. Truong, Vy T. Pham, Binh Q Truong, Quoc Bui, Cassady Palmer
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8838-8845 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8838-8845 (2021)
Background The survival outcome for primary cardiac malignant tumors (PMCTs) based on race has yet to be fully elucidated in previously published literature. This study aimed to address the general long‐term outcome and survival rate differences in
Autor:
Line Wergeland, Siv Lise Bedringaas, Peter J. M. Valk, Adil Al Hinai, Atle Brendehaug, Monica Hellesøy, Caroline Engen, Tim Grob, Bjørn Tore Gjertsen, Randi Hovland
Publikováno v:
Molecular Oncology, 15(9), 2300-2317. John Wiley & Sons Ltd.
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2300-2317 (2021)
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2300-2317 (2021)
Recurrent somatic internal tandem duplications (ITD) in the FMS‐like tyrosine kinase 3 (FLT3) gene characterise approximately one third of patients with acute myeloid leukaemia (AML), and FLT3‐ITD mutation status guides risk‐adapted treatment s
Autor:
Sweety Gupta, Sumit Singh, Atokali Chophy, Sharanya Nair, Rachit Ahuja, K. Kusum, Deepa Joseph, Rajnish Arora, Amit Gupta, Manoj Gupta
Publikováno v:
Journal of the Egyptian National Cancer Institute. 34
Introduction Brain metastases (BM) are associated with dismal prognosis as they cause significant morbidity and affect the quality of life of patients. Management of BM depends on the following factors: age, patient performance, size and the number o
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background There are no epidemiological studies describing rare cancers in Western Australia (WA). We aimed to fill this gap by estimating the incidence and five-year survival of rare, less common and common cancers in WA, based on definitions for ra
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-21 (2021)
BMC Cancer
BMC Cancer
Background Due to its rarity and high heterogeneity, neither established guidelines nor prospective data are currently available for using chemotherapy in the treatment of appendiceal cancer. This study was to determine the use of chemotherapy and it
Autor:
Hsuan-Chih Kuo, Kun-Yun Yeh, Chung-Wei Fan, Yen-Lin Yu, Yi-Ping Pan, Pei-Hung Chang, Wen-Ko Tseng
Publikováno v:
The International Journal of Biological Markers. 36:40-49
Background: The Glasgow Prognostic Score and circulating cytokine levels are related to the prognosis of colorectal cancer and the severity of chronic inflammation. The association between the Glasgow Prognostic Score and circulating cytokines in col
Autor:
Jim Hofferkamp, Oliver Bucher, James Brierley, Freddie Bray, Sean Kehoe, D. Maxwell Parkin, Marion Piñeros, John Butler, Eileen Morgan, Citadel J Cabasag, Melina Arnold, Isabelle Soerjomataram
Publikováno v:
International Journal of Cancer. 149:1239-1246
Cancer stage at diagnosis is important information for management and treatment of individual patients as well as in epidemiological studies to evaluate effectiveness of health care system in managing cancer patients. Population-based studies to exam
Publikováno v:
Clinical and Translational Oncology. 23:2171-2180
APL patients have recurrent alterations in FLT3, WT1, NRAS and KRAS. Gene mutations have a strong potential for involvement in pathogenesis and may have potential effects on the clinical manifestations. Gene mutations may even be associated with earl
Autor:
Satomi Odani, Takahiro Tabuchi, Shihoko Koyama, Toshitaka Morishima, Kayo Nakata, Isao Miyashiro, Sumiyo Okawa
Publikováno v:
Cancer Science
The Japanese national and prefectural governments have accredited high‐capacity, high‐experience cancer care hospitals as “designated cancer care hospitals” to standardize cancer care, centralize patients, and improve clinical outcomes, but t